The quick card
Same conversation. Different products?
Yes. Get the name right before comparing a price, a study or an insurance answer.
Which name means the solo drug?
Cagrilintide is a lab-made version of amylin, the hormone involved in fullness after meals.
As of September 28, 2026, it was still being studied, with no US-approved use.
Open the source note
Cagrilintide alone and CagriSema are different treatments. Check which one an offer names.
Which name means the pair?
CagriSema combines cagrilintide with another medicine, semaglutide, the ingredient in Ozempic and Wegovy.
The maker asked FDA, the US drug agency, to review CagriSema for adult weight care; it remained unapproved on September 28, 2026.
The maker expected FDA to decide in late 2026. FDA could approve or reject it; the date could change.
Open the source note
FDA had not published a decision date by September 28, 2026. The maker’s expected date does not tell you when a pharmacy could supply CagriSema.
Is semaglutide itself different?
Yes: semaglutide has FDA-approved products, including Ozempic and Wegovy, as of September 26, 2026.
Their approved uses differed on September 26, 2026: the Ozempic injection had diabetes-related uses, while Wegovy included weight care.
That is a conversation to have with a prescriber, the health professional who assesses whether a medicine fits.
Open the source note
Sharing an ingredient does not give the products the same approved uses or coverage.